BBIO — BRIDGEBIO PHARMA INC

Ownership history in Nicholas Investment Partners, LP  ·  16 quarters on record

This page tracks every 13F SEC filing in which Nicholas Investment Partners, LP reported a position in BRIDGEBIO PHARMA INC (BBIO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
2.26% (2020 Q4)
Avg. % of fund
0.84%
First filed
2019 Q3
Last filed
2025 Q4
Quarters held
16
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 284,682 +13,052 +4.8% 1.59% $21.8M $76.49
2025 Q3 ADDED 271,630 +112,129 +70.3% 1.08% $14.1M $51.94
2025 Q2 REDUCED 159,501 -7,154 -4.3% 0.61% $6.9M $43.18
2025 Q1 ADDED 166,655 +106,763 +178.3% 0.59% $5.8M $34.57
12 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    BBIO price (monthly, adj. close)

Other funds also holding BBIO

As of 2025 Q4 — sorted by position size

Aisling Capital Management LP 3Y 7Y 81.29% Kohlberg Kravis Roberts & Co. L.P. 3Y 7Y 16.22% Frazier Life Sciences Management, L.P. 3Y 7.28% First Turn Management, LLC 5.2% BOONE CAPITAL MANAGEMENT LLC 3Y 4.44% Eagle Health Investments LP 3Y 4.36% Monashee Investment Management LLC 3Y 7Y 4.31% Cormorant Asset Management, LP 3Y 7Y 4.24% Atle Fund Management AB 3Y 7Y 3.45% Laurion Capital Management LP 3Y 7Y 3.28%
← Back to Nicholas Investment Partners, LP Holdings